Metformin (Glucophage) vs. Glipizide (Glucotrol)
Title: Metformin (Glucophage) vs. Glipizide (Glucotrol)Category: MedicationsCreated: 12/21/2018 12:00:00 AMLast Editorial Review: 12/21/2018 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - December 21, 2018 Category: Endocrinology Source Type: news

Metaglip (Glipizide and Metformin) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 26, 2017 Category: Drugs & Pharmacology Source Type: news

Glucotrol XL (Glipizide Extended Release) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 29, 2016 Category: Drugs & Pharmacology Source Type: news

glipizide and metformin (Metaglip has been discontinued in the US)
Title: glipizide and metformin (Metaglip has been discontinued in the US)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 12/16/2016 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - December 16, 2016 Category: Drugs & Pharmacology Source Type: news

Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies. I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact. Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications. Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news

Sulfonylurea poisoning in a healthy toddler - Kumar S, Choudhary A, Ali M, Gupta V, Muralidharan J, Singhi SC.
Ingestion of sulfonylureas is life-threatening in toddlers and children due to its strong and prolonged hypoglycemic effect. The authors present a 15-mo-old boy with accidental ingestion of Glipizide who presented with encephalopathy, seizure and severe hy... (Source: SafetyLit)
Source: SafetyLit - November 6, 2016 Category: Global & Universal Tags: Age: Infants and Children Source Type: news

Actavis recalls diabetes drugs made by Durham-based Patheon
Actavis, the generic drug unit that Allergan (NYSE: AGN) recently sold to Teva Pharmaceutical Industries (NYSE: TEVA), has recalled five lots of a diabetes drug that were manufactured under a contract by Durham-based Patheon (NYSE: PTHN). According to Patheon, a problem with the diabetes drug Glipizide arose after the size of the pill bottle was increased, and a drying agent was included in the new bottle. “The issue was not related to the manufacturing or packaging services provided by Patheon,”… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 19, 2016 Category: Biotechnology Authors: Jason deBruyn Source Type: news

Actavis recalls diabetes drugs made by Durham-based Patheon
Actavis, the generic drug unit that Allergan (NYSE: AGN) recently sold to Teva Pharmaceutical Industries (NYSE: TEVA), has recalled five lots of a diabetes drug that were manufactured under a contract by Durham-based Patheon (NYSE: PTHN). According to Patheon, a problem with the diabetes drug Glipizide arose after the size of the pill bottle was increased, and a drying agent was included in the new bottle. “The issue was not related to the manufacturing or packaging services provided by Patheon,”… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 19, 2016 Category: Pharmaceuticals Authors: Jason deBruyn Source Type: news

Risk of low blood sugar differs among similar diabetes drugs
Adding sulphonylureas (SUs) to metformin remains a commonly used strategy for treating type 2 diabetes, but individual SUs differ and may confer different risks of abnormally low blood sugar, or hypoglycemia. SUs -- which include newer generation agents such as gliclazide, glipizide, glimepiride, and glibenclamide -- stimulate the production of insulin in the pancreas and increase the effectiveness of insulin in the body. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 19, 2016 Category: Science Source Type: news

Glucotrol (Glipizide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 8, 2016 Category: Drugs & Pharmacology Source Type: news

glipizide/metformin (Metaglip has been discontinued in the US)
Title: glipizide/metformin (Metaglip has been discontinued in the US)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 5/19/2016 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - May 19, 2016 Category: Endocrinology Source Type: news

Oral agents offer glycemic control, improved beta-cell function in severe hyperglycemia
The combination DPP-IV inhibitor plus metformin Kombiglyze XR was as effective as glipizide XL in lowering blood glucose and improving beta-cell function in patients with newly diagnosed type-2 diabetes and severe hyperglycemia, according to recently published results in JCEM. Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 11, 2016 Category: Endocrinology Source Type: news

Warfarin, Sulfonylurea Combo Ups Severe Hypoglycemia Risk Warfarin, Sulfonylurea Combo Ups Severe Hypoglycemia Risk
The findings suggest a unique drug-drug interaction between warfarin and glipizide/glimepiride, with the greatest hypoglycemia risk at start of warfarin treatment. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 21, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Glucotrol XL (Glipizide Extended Release) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 1, 2015 Category: Drugs & Pharmacology Source Type: news

glipizide/metformin (Metaglip)
Title: glipizide/metformin (Metaglip)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 2/5/2015 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - February 5, 2015 Category: Drugs & Pharmacology Source Type: news

glipizide/metformin (Metaglip)
Title: glipizide/metformin (Metaglip)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 2/5/2015 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - February 5, 2015 Category: Endocrinology Source Type: news

glipizide, Glipizide XL, Glucotrol, Glucotrol XL
Title: glipizide, Glipizide XL, Glucotrol, Glucotrol XLCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 12/11/2014 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - December 11, 2014 Category: Drugs & Pharmacology Source Type: news

glipizide, Glipizide XL, Glucotrol, Glucotrol XL
Title: glipizide, Glipizide XL, Glucotrol, Glucotrol XLCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 12/11/2014 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - December 11, 2014 Category: Endocrinology Source Type: news

JANUVIA (Sitagliptin) Compared With Sulfonylurea For Patients With Type 2 Diabetes And Mild Renal Impairment
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA® (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain. Results were presented at the American Diabetes Association 73rd Scientific Sessions... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 25, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news

New analysis shows that patients with Type 2 diabetes and mild renal impairment had similar improvement in blood sugar control and experienced less hypoglycemia with JANUVIA (sitagliptin) compared to sulfonylurea
(GCI Health NY) Merck, known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with Type 2 diabetes and mild renal impairment treated with JANUVIA (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia, and with weight loss instead of weight gain. Results were presented at the American Diabetes Association 73rd Scientific Sessions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 22, 2013 Category: Global & Universal Source Type: news

Metformin Superior to Glipizide in Diabetics With CADMetformin Superior to Glipizide in Diabetics With CAD
Over a median follow-up of five years, treatment with metformin reduced the primary composite end point of death from cardiovascular causes, death from any cause, nonfatal MI, nonfatal stroke, and arterial revascularization by 46% compared with glipizide. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 3, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Metformin superior to glipizide for reducing CVD events in diabetics with CAD
Over a median follow-up of five years, treatment with metformin reduced the primary composite end point of death from cardiovascular causes, death from any cause, nonfatal MI, nonfatal stroke, and arterial revascularization by 46% compared with glipizide. (Source: theHeart.org)
Source: theHeart.org - January 3, 2013 Category: Cardiology Source Type: news

Diabetics have fewer cardiovascular events with metformin than with glipizide
NEW YORK (Reuters Health) - Compared with glipizide, long-term therapy with metformin leads to a reduction in major cardiovascular events in patients with type 2 diabetes, according to Chinese and US researchers. (Source: Modern Medicine)
Source: Modern Medicine - January 1, 2013 Category: Journals (General) Source Type: news